IGM Biosciences, Inc. (IGMS)
NASDAQ: IGMS · Real-Time Price · USD
1.240
-0.040 (-3.13%)
Mar 28, 2025, 4:00 PM EDT - Market closed
IGM Biosciences Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for IGM Biosciences stock have an average target of 6.14, with a low estimate of 1.50 and a high estimate of 22. The average target predicts an increase of 395.16% from the current stock price of 1.24.
Analyst Consensus: Hold
* Price targets were last updated on Jan 10, 2025.
Analyst Ratings
The average analyst rating for IGM Biosciences stock from 8 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
---|---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 0 | 0 | 0 |
Buy | 2 | 2 | 3 | 1 | 1 | 1 |
Hold | 4 | 4 | 3 | 7 | 7 | 7 |
Sell | 1 | 1 | 1 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 8 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
JP Morgan | JP Morgan | Sell → Hold Upgrades n/a | Sell → Hold | Upgrades | n/a | n/a | Jan 13, 2025 |
Jefferies | Jefferies | Strong Buy → Hold Downgrades $48 → $2 | Strong Buy → Hold | Downgrades | $48 → $2 | +61.29% | Jan 10, 2025 |
Truist Securities | Truist Securities | Hold Maintains $12 → $2 | Hold | Maintains | $12 → $2 | +61.29% | Jan 10, 2025 |
Stifel | Stifel | Strong Buy → Hold Downgrades $27 → $2.5 | Strong Buy → Hold | Downgrades | $27 → $2.5 | +101.61% | Jan 10, 2025 |
RBC Capital | RBC Capital | Buy → Hold Downgrades $20 → $1.5 | Buy → Hold | Downgrades | $20 → $1.5 | +20.97% | Jan 10, 2025 |
Financial Forecast
Revenue This Year
6.29M
from 2.68M
Increased by 134.71%
Revenue Next Year
10.96M
from 6.29M
Increased by 74.27%
EPS This Year
-0.98
from -3.24
EPS Next Year
-0.62
from -0.98
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 24.8M | 33.3M | 66.9M | ||
Avg | 6.3M | 11.0M | 20.9M | ||
Low | n/a | n/a | 2.4M |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 826.8% | 430.2% | 510.9% | ||
Avg | 134.7% | 74.3% | 90.6% | ||
Low | - | - | -78.3% |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -0.09 | -0.06 | -0.04 | ||
Avg | -0.98 | -0.62 | -0.85 | ||
Low | -1.98 | -2.24 | -2.68 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.